The combination of Pyrotinib and Trastuzumab can more comprehensively block the HER2 signaling pathway, effectively inhibit tumor cell proliferation and survival, and reduce tumor cell secretion of immunosuppressive factors.4,5,19,20 This also helps to relieve the inhibition of T cells, resulting in higher activity and quantity of T cells in the combined group compared to the simple group.. The gene discussed is ERBB2; the disease is neoplasm.